A novel culture method of canine peripheral blood lymphocytes with concanavalin a and recombinant human interleukin-2 for adoptive immunotherapy

被引:14
作者
Kato, Masahiro
Watarai, Shinobu
Nishikawa, Shigeru
Iwasaki, Tadashi
Kodama, Hiroshi
机构
[1] Osaka Prefecture Univ, Lab Vet Immunol, Div Vet Sci, Grad Sch Life & Environm Sci, Sakai, Osaka 5998531, Japan
[2] Noda Hanshin Anim Hosp, Fukushima Ku, Osaka 5530007, Japan
关键词
canine; concanavalin A; interleukin-2; LAK cell; lymphocyte;
D O I
10.1292/jvms.69.481
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
This study was designed to develop a novel culture method for the efficient proliferation of canine peripheral blood lymphocytes (cPBL) for adoptive immunotherapy. When cPBL were cultured in the presence of concanavalin A (Con A), proliferation of cPBL was induced and expression of interleukin-2 receptor (IL-2R) which enables to respond to exogenously added IL-2 was upregulated. And then, when cPBL were cultured with recombinant human interleukin-2 (rhIL-2) in addition to Con A, proliferation was accelerated and increased to about 10-fold after 1 week. The phenotypic analysis showed that the main population of the cultured cPBL was consisted of CD8+ positive lymphocytes. Among them, CD4+CD8+ double positive (DP) lymphocytes had significantly increased, and the ratio of CD4+ single positive (SP) lymphocytes to CD8+ SP lymphocytes (CD4+SP/CD8+SP) was decreased as compared to before culturing. To evaluate the cytotoxic activity of cPBL cultured with Con A and rhIL-2, furthermore, cytotoxic assay was carried out against xenogeneic melanoma cell line (MeWo), which resulted in MHC-unrestrieted cytokilling. These results suggest that the culture method of cPBL by the use of Con A and rhIL-2 may be useful for generating lymphokine activated killer cells, and also this may be beneficial for adoptive immunotherapy of tumor-bearing dogs.
引用
收藏
页码:481 / 486
页数:6
相关论文
共 35 条
[1]  
BEVAN MJ, 1975, J IMMUNOL, V114, P559
[2]   Potential to target dysregulated interleukin-2 receptor expression in canine lymphoid and hematopoietic malignancies as a model for human cancer [J].
Dickerson, KB ;
Fosmire, S ;
Padilla, ML ;
Modiano, JF ;
Helfand, SC .
JOURNAL OF IMMUNOTHERAPY, 2002, 25 (01) :36-45
[3]   Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels [J].
Ebina, T ;
Ogama, N ;
Shimanuki, H ;
Kubota, T ;
Isono, N .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2003, 52 (09) :555-560
[4]   Effector mechanism and clinical response of BAK (BRM-activated killer) immuno-cell therapy for maintaining satisfactory QOL of advanced cancer patients utilizing CD56-positive NIE (neuro-immune-endocrine) cells [J].
Ebina, T ;
Ogama, N ;
Shimanuki, H ;
Kubota, T ;
Isono, N .
MICROBIOLOGY AND IMMUNOLOGY, 2001, 45 (05) :403-411
[5]   LECTIN-DEPENDENT CELL-MEDIATED CYTO-TOXICITY - A NEW AND SIMPLE METHOD TO QUANTITATE CYTO-TOXIC T-CELL ACTIVITY IN DOGS [J].
EMESON, EE ;
NORIN, AJ ;
VEITH, FJ .
TRANSPLANTATION, 1982, 33 (04) :365-369
[6]  
Falk CS, 2002, CANCER RES, V62, P480
[7]   HUMAN RECOMBINANT INTERLEUKIN-2(125) INDUCED INVITRO PROLIFERATION OF EQUINE, CAPRINE, OVINE, CANINE AND FELINE PERIPHERAL-BLOOD LYMPHOCYTES [J].
FENWICK, BW ;
SCHORE, CE ;
OSBURN, BI .
COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 1988, 11 (01) :51-60
[8]   Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms [J].
Funk, J ;
Schmitz, G ;
Failing, K ;
Burkhardt, E .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (01) :87-92
[9]  
GRIMM EA, 1986, BIOCHIM BIOPHYS ACTA, V865, P267
[10]   LYMPHOKINE-ACTIVATED KILLER CELL PHENOMENON - LYSIS OF NATURAL KILLER-RESISTANT FRESH SOLID TUMOR-CELLS BY INTERLEUKIN 2-ACTIVATED AUTOLOGOUS HUMAN PERIPHERAL-BLOOD LYMPHOCYTES [J].
GRIMM, EA ;
MAZUMDER, A ;
ZHANG, HZ ;
ROSENBERG, SA .
JOURNAL OF EXPERIMENTAL MEDICINE, 1982, 155 (06) :1823-1841